The membrane-proximal external region of the human immunodeficiency virus type 1 envelope: dominant site of antibody neutralization and target for vaccine design
about
Cryoelectron tomography of HIV-1 envelope spikes: further evidence for tripod-like legsPolyclonal B cell responses to conserved neutralization epitopes in a subset of HIV-1-infected individualsCurrent Advances in Virus-Like Particles as a Vaccination Approach against HIV InfectionInduction of antibodies in rhesus macaques that recognize a fusion-intermediate conformation of HIV-1 gp41A Conformational Switch in Human Immunodeficiency Virus gp41 Revealed by the Structures of Overlapping Epitopes Recognized by Neutralizing AntibodiesCrystallographic Definition of the Epitope Promiscuity of the Broadly Neutralizing Anti-Human Immunodeficiency Virus Type 1 Antibody 2F5: Vaccine Design ImplicationsStructure and function of broadly reactive antibody PG16 reveal an H3 subdomain that mediates potent neutralization of HIV-1Charge-Surrounded Pockets and Electrostatic Interactions with Small Ions Modulate the Activity of Retroviral Fusion ProteinsStructure-Based Design of a Protein Immunogen that Displays an HIV-1 gp41 Neutralizing EpitopeStructure and Immunogenicity of a Peptide Vaccine, Including the Complete HIV-1 gp41 2F5 EpitopeNeutralization of tier-2 viruses and epitope profiling of plasma antibodies from human immunodeficiency virus type 1 infected donors from IndiaRecognition of membrane-bound fusion-peptide/MPER complexes by the HIV-1 neutralizing 2F5 antibody: implications for anti-2F5 immunogenicityBroad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine targetMapping of Ebolavirus Neutralization by Monoclonal Antibodies in the ZMapp Cocktail Using Cryo-Electron Tomography and Studies of Cellular EntryRecent advances on the use of structural biology for the design of novel envelope immunogens of HIV-1Generation of Long-Lived Bone Marrow Plasma Cells Secreting Antibodies Specific for the HIV-1 gp41 Membrane-Proximal External Region in the Absence of Polyreactivity.Antibody response to polyhistidine-tagged peptide and protein antigens attached to liposomes via lipid-linked nitrilotriacetic acid in mice.C-terminal tail of human immunodeficiency virus gp41: functionally rich and structurally enigmatic.A human antibody to the CD4 binding site of gp120 capable of highly potent but sporadic cross clade neutralization of primary HIV-1.Broad neutralization of human immunodeficiency virus type 1 (HIV-1) elicited from human rhinoviruses that display the HIV-1 gp41 ELDKWA epitopeFunctional, non-clonal IgMa-restricted B cell receptor interactions with the HIV-1 envelope gp41 membrane proximal external region.Candidate vaccine sequences to represent intra- and inter-clade HIV-1 variation.4E10-resistant HIV-1 isolated from four subjects with rare membrane-proximal external region polymorphismsAromatic residues at the edge of the antibody combining site facilitate viral glycoprotein recognition through membrane interactions.Prolonged exposure of the HIV-1 gp41 membrane proximal region with L669S substitutionAnti-gp41 antibodies cloned from HIV-infected patients with broadly neutralizing serologic activityHIV-1 gp41 core with exposed membrane-proximal external region inducing broad HIV-1 neutralizing antibodiesInduction of HIV neutralizing antibodies against the MPER of the HIV envelope protein by HA/gp41 chimeric protein-based DNA and VLP vaccinesAntibody to gp41 MPER alters functional properties of HIV-1 Env without complete neutralizationCross-reactive HIV-1-neutralizing human monoclonal antibodies identified from a patient with 2F5-like antibodies.Chemically modified peptides based on the membrane-proximal external region of the HIV-1 envelope induce high-titer, epitope-specific nonneutralizing antibodies in rabbitsNef decreases HIV-1 sensitivity to neutralizing antibodies that target the membrane-proximal external region of TMgp41.Requirements for empirical immunogenicity trials, rather than structure-based design, for developing an effective HIV vaccine.Evaluation of the potency of the anti-idiotypic antibody Ab2/3H6 mimicking gp41 as an HIV-1 vaccine in a rabbit prime/boost studyIdentification of autoantigens recognized by the 2F5 and 4E10 broadly neutralizing HIV-1 antibodiesHIV vaccines: lessons learned and the way forward.A fusion intermediate gp41 immunogen elicits neutralizing antibodies to HIV-1The stem of vesicular stomatitis virus G can be replaced with the HIV-1 Env membrane-proximal external region without loss of G function or membrane-proximal external region antigenic properties.Identification of a new epitope for HIV-neutralizing antibodies in the gp41 membrane proximal external region by an Env-tailored phage display library.Designing a soluble near full-length HIV-1 gp41 trimer.
P2860
Q21090520-CB43B6C8-1056-4EFD-B8C2-711599E0B6F0Q24635002-CD6D8DD3-FB0A-4DB2-B5DD-ACEB2C3587D0Q26775082-7A4192D8-D0FC-4F7D-AEA7-BEC557B3D2E3Q27312171-7AD4A041-EA58-48D9-BB77-859BBAC1FC36Q27655865-65C14C62-A255-4F6F-AD5B-EA2A17B677F3Q27657377-E922727C-81E5-442E-938F-918E368A6787Q27662155-FD82CC5E-BB7F-4B93-847C-5EECF248D4B6Q27666913-F485B431-4E5A-47D0-BF0A-BF59BF94F761Q27675260-C6CCD4EC-056E-4436-8517-C4B6F6042486Q27681352-A4BFDAFE-66A4-4631-8264-E1AAB1094EAEQ28483205-C462BA84-B393-4EE2-8BC9-DC963EDD6465Q28484544-9C2AD04E-55E0-4A22-B8DF-44BBA6552D21Q29547347-2A42C139-089A-4F15-B3AB-DA81B72FBECAQ30276615-7219B856-B1E6-4EE2-AEF9-4010E639B027Q30353580-7070CFCE-E6DF-4977-B2A7-30FFF69D673BQ30391094-102B828B-4EBB-468C-93FF-380FB88FD46CQ30397437-8E979EA4-63A5-43A9-9546-1EE7B291E6A9Q30422545-05BE5571-B607-4DCB-AAF4-2018C48B7B6EQ31132248-958E81A7-BE27-4858-BCD5-04C0DA426C52Q33417195-E134837D-85B6-4007-BEAA-87250911217AQ33508799-176612AA-8A84-4D17-9F82-0C1CDE1602C1Q33509288-5F2F6900-BFF9-4127-8F77-09078E525CD1Q33547451-82B0C718-14CD-4973-A3D0-56D188B892D1Q33667654-4AF064A4-4398-4039-B436-A3704101656BQ33778466-5E3C03F8-DD3C-4A00-9B8C-BD7E65BA66CDQ33826951-A4D4E45E-AAE0-4D1D-8E02-E706FD3FFF22Q33869882-5C47CBF6-F889-46FC-929B-868EBAEEF204Q33916676-7F07809A-5457-4765-BB52-FB221ED7E3B3Q33946158-9F1FF908-5320-469A-9E31-DEB886D8F68AQ34006748-492AC804-0FE4-469F-9098-1C73EDEE86A1Q34057672-730D69F9-0AEA-435A-8A0D-2412F07CD7FDQ34109778-E12BEBAF-DC26-4AA5-96C1-7C88DE140EE8Q34225659-BDC437AF-F85D-4CA6-9FDB-3FEAD62360EFQ34312108-0ADAC295-337F-4DFE-8DA5-F816CFC27C26Q34324992-EC8E2BC2-E68A-4FE8-8A27-88A089D64739Q34342558-E7BA4AC5-DBE2-4A4F-873A-A2B52C41D20CQ34396912-1F2EFEEA-1DC7-47DA-8F1F-2EDBF1D0719FQ34399656-FBFE2C9E-D51C-46FC-86FD-9984EF0AC619Q34488183-C92A87D9-B9D6-45EE-B4F7-660BF0DC6CF4Q34489464-B11EA62A-68A9-4EA8-9199-D26E009A11FB
P2860
The membrane-proximal external region of the human immunodeficiency virus type 1 envelope: dominant site of antibody neutralization and target for vaccine design
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
The membrane-proximal external ...... and target for vaccine design
@ast
The membrane-proximal external ...... and target for vaccine design
@en
type
label
The membrane-proximal external ...... and target for vaccine design
@ast
The membrane-proximal external ...... and target for vaccine design
@en
prefLabel
The membrane-proximal external ...... and target for vaccine design
@ast
The membrane-proximal external ...... and target for vaccine design
@en
P2093
P2860
P356
P1476
The membrane-proximal external ...... and target for vaccine design
@en
P2093
Jamie K Scott
Marinieve Montero
Nienke E van Houten
P2860
P304
54-84, table of contents
P356
10.1128/MMBR.00020-07
P577
2008-03-01T00:00:00Z